I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on both our cell therapy and small molecule clinical programs. We have just completed all the transplantations of our phase two ALS patients, with the data lock coming early in …Read More
Knoepfler lab stem cell blog
